ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0029

A Retrospective Cohort Study of Chemotherapy-Related AKI

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Kang, Xin, Renal Division, Peking University First Hospital, Peking University, Beijing, China
  • Yang, Li, Renal Division, Peking University First Hospital, Peking University, Beijing, China

Chemotherapy-related acute kidney injury (CR-AKI) is increasing with the growing number of cancer patients and the development of chemotherapeutic agents, whereas systemic information about CR-AKI is still limited.


This is a multicenter retrospective cohort study of cancer patients with CR-AKI screened from a cohort of hospital-acquired adult AKI patients based on a nationwide AKI survey in China. The enrolled CR-AKI patients were divided into three groups according to peak AKI stages (1 to 3) during hospitalization. The primary outcome was all-cause death in hospital, and the secondary outcome was AKI recovery.


Of 3,468 adult inpatients with hospital-acquired AKI identified basing on the China nationwide AKI survey, 258 patients with CR-AKI were enrolled in our study, of which 20.1% (52/258) were ≥ 70 years old. A total of 413 person-time chemotherapeutic agents were related to AKI, of which platinum compounds (24.5%, 101/413) were the most common ones, followed by fluoropyrimidines (13.1%, 54/413), and anthracyclines (9.2%, 38/413). Among the 258 CR-AKI patients, 61 (23.0%) reached AKI stage 3, and 12 (4.7%) received RRT. The in-hospital mortality was 14.7% (38/258). Of the 207 surviving patients with a reliable serum creatinine value at discharge, 48.3% (100/207) failed to renal recovery. AKI stage 3 remained the independent risk factor for in-hospital death (OR 2.930, 95%CI 1.156~7.427) after adjustment for gender, age, comorbidities, and medications. It is surprising to note that, although patients of AKI stage 1 had lower levels of SCr both at peak and at discharge compared to patients with AKI stage 2 or 3, there was a higher proportion of patients of AKI stage 1 not achieving renal function significantly improved at discharge (failure to recover) compared to those of AKI stage 2 or 3 (57.1% vs. 41.4% vs. 36.4%, P = 0.032). More importantly, a lot more AKI episodes were not recognized or diagnosed by physicians in charge in patients of AKI stage 1 compared to the other two groups (82.8% vs. 60.0% vs. 36.1%, P < 0.001).


CR-AKI accounted for a considerable proportion of hospital-acquired AKI. Severe CR-AKI increases in-hospital mortality. Mild CR-AKI that overlooked by physicians yet sustained kidney injury was common in these patients. Recognizing CR-AKI at an early stage and making personalized treatment should be emphasized when offering chemotherapy to patients.